Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma

[1]  R. Lai,et al.  Pathobiology of ALK+ anaplastic large-cell lymphoma. , 2007, Blood.

[2]  P. Gaulard,et al.  Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. , 2007, Blood.

[3]  P Wlodarski,et al.  Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf , 2007, Oncogene.

[4]  Markus Essler,et al.  IL-22-Mediated Tumor Growth Reduction Correlates with Inhibition of ERK1/2 and AKT Phosphorylation and Induction of Cell Cycle Arrest in the G2-M Phase , 2006, The Journal of Immunology.

[5]  S. Brand,et al.  IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[6]  R. Lai,et al.  Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. , 2006, Blood.

[7]  J. Mackey,et al.  Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. , 2006, The American journal of pathology.

[8]  K. Asadullah,et al.  IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis , 2006, European journal of immunology.

[9]  A. Takayanagi,et al.  Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. , 2005, Gastroenterology.

[10]  D. Levy,et al.  Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target , 2005, Nature Medicine.

[11]  K. Hiromura,et al.  Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. , 2005, Arthritis and rheumatism.

[12]  K. Asadullah,et al.  Is there an interaction between interleukin-10 and interleukin-22? , 2005, Genes and Immunity.

[13]  T. McDonnell,et al.  Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma , 2004, Oncogene.

[14]  A. Gurney.  IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues. , 2004, International immunopharmacology.

[15]  R. de Waal Malefyt,et al.  Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. , 2004, International immunopharmacology.

[16]  C. Lyle,et al.  Inhibition of Cell Proliferation and Cell Cycle Progression by Specific Inhibition of Basal JNK Activity , 2004, Journal of Biological Chemistry.

[17]  Marlene Wolf,et al.  Chemokines: multiple levels of leukocyte migration control. , 2004, Trends in immunology.

[18]  G. Delsol,et al.  Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. , 2003, Blood.

[19]  T. McDonnell,et al.  Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma , 2003, Oncogene.

[20]  Diane Lejeune,et al.  Interleukin-22 (IL-22) Activates the JAK/STAT, ERK, JNK, and p38 MAP Kinase Pathways in a Rat Hepatoma Cell Line , 2002, The Journal of Biological Chemistry.

[21]  K. Asadullah,et al.  Cutting Edge: Immune Cells as Sources and Targets of the IL-10 Family Members? , 2002, The Journal of Immunology.

[22]  S. Kotenko.  The family of IL-10-related cytokines and their receptors: related, but to what extent? , 2002, Cytokine & growth factor reviews.

[23]  D. Levy,et al.  What does Stat3 do? , 2002, The Journal of clinical investigation.

[24]  B. Falini,et al.  Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. , 2002, Cancer research.

[25]  D. Levy,et al.  Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death , 2002, Oncogene.

[26]  Qian Zhang,et al.  Multilevel Dysregulation of STAT3 Activation in Anaplastic Lymphoma Kinase-Positive T/Null-Cell Lymphoma1 , 2002, The Journal of Immunology.

[27]  Jiayuh Lin,et al.  Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells , 2001, Oncogene.

[28]  K. Asadullah,et al.  A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta , 2001, Genes and Immunity.

[29]  D. Lejeune,et al.  Cloning and Characterization of IL-22 Binding Protein, a Natural Antagonist of IL-10-Related T Cell-Derived Inducible Factor/IL-22 , 2001, The Journal of Immunology.

[30]  M. Wasik,et al.  Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. , 2001, Cancer research.

[31]  S. Pestka,et al.  Identification of the Functional Interleukin-22 (IL-22) Receptor Complex , 2001, The Journal of Biological Chemistry.

[32]  Zemin Zhang,et al.  Interleukin (IL)-22, a Novel Human Cytokine That Signals through the Interferon Receptor-related Proteins CRF2–4 and IL-22R* , 2000, The Journal of Biological Chemistry.

[33]  Jamila Louahed,et al.  Cloning and Characterization of IL-10-Related T Cell-Derived Inducible Factor (IL-TIF), a Novel Cytokine Structurally Related to IL-10 and Inducible by IL-91 , 2000, The Journal of Immunology.

[34]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[35]  K. Todokoro,et al.  Requirement of activation of JNK and p38 for environmental stress-induced erythroid differentiation and apoptosis and of inhibition of ERK for apoptosis. , 1999, Blood.

[36]  H. Satoh,et al.  Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. , 1994, Oncogene.

[37]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[38]  R. Lai,et al.  Restoration of shp1 expression by 5-AZA-2′-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma , 2006, Leukemia.

[39]  Jiahuai Han,et al.  The p38 signal transduction pathway: activation and function. , 2000, Cellular signalling.

[40]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.